Gamida Cell Ltd. (GMDA)
0.03
-0.00 (-8.26%)
At close: Jan 16, 2025, 9:00 PM
-8.26% (1D)
| Bid | n/a |
| Market Cap | 4.34M |
| Revenue (ttm) | 2.67M |
| Net Income (ttm) | -22.09M |
| EPS (ttm) | -0.82 |
| PE Ratio (ttm) | -0.039878048780487806 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 23,036,893 |
| Avg. Volume (20D) | 9,670,277 |
| Open | 0.04 |
| Previous Close | 0.03 |
| Day's Range | 0.03 - 0.04 |
| 52-Week Range | 0.01 - 2.51 |
| Beta | 1.03 |
About GMDA
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based can...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 26, 2018
Employees 143
Stock Exchange NASDAQ
Ticker Symbol GMDA
Website https://www.gamida-cell.com